Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 352

1.

Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma.

Figlin RA, Tannir NM, Uzzo RG, Tykodi SS, Chen DYT, Master V, Kapoor A, Vaena D, Lowrance WT, Bratslavsky G, DeBenedette M, Gamble A, Plachco A, Norris MS, Horvatinovich J, Tcherepanova IY, Nicolette CA, Wood CG.

Clin Cancer Res. 2020 Feb 7. pii: clincanres.2427.2019. doi: 10.1158/1078-0432.CCR-19-2427. [Epub ahead of print]

PMID:
32034074
2.

EDITORIAL COMMENT.

Shapiro DD, Karam JA, Wood CG.

Urology. 2020 Feb;136:175. doi: 10.1016/j.urology.2019.08.059. No abstract available.

PMID:
32033671
3.

PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy.

Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, Shariat SF, Hsieh JT, Wu WJ.

Urol Oncol. 2019 Dec 17. pii: S1078-1439(19)30483-1. doi: 10.1016/j.urolonc.2019.11.010. [Epub ahead of print]

PMID:
31862213
4.

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).

Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2019 Dec 20;7(1):354. doi: 10.1186/s40425-019-0813-8.

5.

Predicting Adherent Perinephric Fat Using Preoperative Clinical and Radiological Factors in Patients Undergoing Partial Nephrectomy.

Borregales LD, Adibi M, Thomas AZ, Reis RB, Chery LJ, Devine CE, Wang X, Potretzke AM, Potretzke T, Figenshau RS, Bauman TM, Aboshady YI, Abel EJ, Matin SF, Karam JA, Wood CG.

Eur Urol Focus. 2019 Nov 1. pii: S2405-4569(19)30328-1. doi: 10.1016/j.euf.2019.10.007. [Epub ahead of print]

PMID:
31685445
6.

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.

Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG.

J Urol. 2020 Apr;203(4):684-689. doi: 10.1097/JU.0000000000000588. Epub 2019 Oct 9.

PMID:
31596672
7.

Pancreatitis in the developmentally anomalous pancreas.

Wood CG, Lopes Vendrami C, Craig E, Mittal PK, Miller FH.

Abdom Radiol (NY). 2019 Aug 29. doi: 10.1007/s00261-019-02197-8. [Epub ahead of print] Review.

PMID:
31468154
8.

Extensive intraspecies cryptic variation in an ancient embryonic gene regulatory network.

Torres Cleuren YN, Ewe CK, Chipman KC, Mears ER, Wood CG, Al-Alami CEA, Alcorn MR, Turner TL, Joshi PM, Snell RG, Rothman JH.

Elife. 2019 Aug 15;8. pii: e48220. doi: 10.7554/eLife.48220.

9.

Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia.

Zacharias NM, Baran N, Shanmugavelandy SS, Lee J, Lujan JV, Dutta P, Millward SW, Cai T, Wood CG, Piwnica-Worms D, Konopleva M, Bhattacharya PK.

Mol Cancer Ther. 2019 Nov;18(11):1937-1946. doi: 10.1158/1535-7163.MCT-18-0985. Epub 2019 Aug 6.

10.

Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.

Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ.

Eur Urol Oncol. 2019 Jul 1. pii: S2588-9311(19)30079-3. doi: 10.1016/j.euo.2019.06.004. [Epub ahead of print]

PMID:
31272939
11.

Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.

Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, Singh RR, Kim TB, Kawakami F, Routbort MJ, Alouch N, Chow CB, Tang X, Lu W, Brimo F, Matin SF, Wood CG, Tannir NM, Wistuba II, Chen K, Wang J, Medeiros LJ, Karam JA, Tamboli P, Sircar K.

Mod Pathol. 2019 Nov;32(11):1698-1707. doi: 10.1038/s41379-019-0304-y. Epub 2019 Jun 23.

PMID:
31231128
12.

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG.

J Clin Oncol. 2019 Aug 10;37(23):2062-2071. doi: 10.1200/JCO.19.00107. Epub 2019 Jun 19.

13.

Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review.

Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich BC, Ljungberg B, Van Poppel H, Bensalah K; Young Academic Urologists Kidney Cancer Working Group of the European Association of Urology.

Eur Urol Oncol. 2019 Mar;2(2):141-149. doi: 10.1016/j.euo.2018.08.028. Epub 2018 Sep 24. Review.

PMID:
31017089
14.

Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM.

World J Urol. 2019 Nov;37(11):2419-2427. doi: 10.1007/s00345-019-02678-x. Epub 2019 Feb 13.

PMID:
30759271
15.

Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy.

Zacharias NM, Ornelas A, Lee J, Hu J, Davis JS, Uddin N, Pudakalakatti S, Menter DG, Karam JA, Wood CG, Hawk ET, Kopetz S, Vilar E, Bhattacharya PK, Millward SW.

Angew Chem Int Ed Engl. 2019 Mar 22;58(13):4179-4183. doi: 10.1002/anie.201812759. Epub 2019 Feb 20.

16.

Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review.

McCormick B, Meissner MA, Karam JA, Wood CG.

Kidney Cancer. 2017 Nov 27;1(2):115-121. doi: 10.3233/KCA-170016.

17.

Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging.

Yu KJ, Keskin SK, Meissner MA, Petros FG, Wang X, Borregales LD, Gu C, Tamboli P, Matin SF, Wood CG, Karam JA.

Cancer. 2018 Oct 15;124(20):4023-4031. doi: 10.1002/cncr.31661. Epub 2018 Oct 1.

18.

The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.

Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE.

Eur Urol Focus. 2020 Jan 15;6(1):104-111. doi: 10.1016/j.euf.2018.08.023. Epub 2018 Sep 8.

PMID:
30206003
19.

Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence.

Zhang J, Ye Y, Chang DW, Lin SH, Huang M, Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN, Wu X.

Am J Pathol. 2018 Nov;188(11):2487-2496. doi: 10.1016/j.ajpath.2018.07.026. Epub 2018 Sep 8.

20.

Conditional survival of patients with small renal masses undergoing active surveillance.

Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, Wood CG, Matin SF.

BJU Int. 2019 Mar;123(3):447-455. doi: 10.1111/bju.14486. Epub 2018 Aug 27.

21.

Salvage topical therapy for upper tract urothelial carcinoma.

Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

World J Urol. 2018 Dec;36(12):2027-2034. doi: 10.1007/s00345-018-2349-9. Epub 2018 May 26.

22.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7.

PMID:
29748098
23.

Adjuvant therapy for advanced renal cell carcinoma.

Meissner MA, McCormick BZ, Karam JA, Wood CG.

Expert Rev Anticancer Ther. 2018 Jul;18(7):663-671. doi: 10.1080/14737140.2018.1469980. Epub 2018 May 2. Review.

PMID:
29707987
24.

Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome.

Shu X, Gu J, Huang M, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X, Ye Y.

Carcinogenesis. 2018 May 28;39(6):752-757. doi: 10.1093/carcin/bgy021.

25.

Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes.

Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG.

Urology. 2018 Jun;116:114-119. doi: 10.1016/j.urology.2018.03.017. Epub 2018 Mar 22.

PMID:
29578041
26.

Oncologic outcomes of patients with positive surgical margin after partial nephrectomy: a 25-year single institution experience.

Petros FG, Metcalfe MJ, Yu KJ, Keskin SK, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG.

World J Urol. 2018 Jul;36(7):1093-1101. doi: 10.1007/s00345-018-2241-7. Epub 2018 Feb 27.

PMID:
29488096
27.

Reactions to Both Nonionic Iodinated and Gadolinium-Based Contrast Media: Incidence and Clinical Characteristics.

Sodagari F, Mozaffary A, Wood CG 3rd, Schmitz B, Miller FH, Yaghmai V.

AJR Am J Roentgenol. 2018 Apr;210(4):715-719. doi: 10.2214/AJR.17.18655. Epub 2018 Feb 7.

PMID:
29412016
28.

BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation.

Pan T, Lin SC, Yu KJ, Yu G, Song JH, Lewis VO, Bird JE, Moon B, Lin PP, Tannir NM, Jonasch E, Wood CG, Gallick GE, Yu-Lee LY, Lin SH, Satcher RL.

Neoplasia. 2018 Jan;20(1):32-43. doi: 10.1016/j.neo.2017.11.002. Epub 2017 Nov 27.

29.

Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

Chipollini J, Abel EJ, Peyton CC, Boulware DC, Karam JA, Margulis V, Master VA, Zargar-Shoshtari K, Matin SF, Sexton WJ, Raman JD, Wood CG, Spiess PE.

Clin Genitourin Cancer. 2018 Apr;16(2):e443-e450. doi: 10.1016/j.clgc.2017.10.004. Epub 2017 Oct 17.

PMID:
29113770
30.

Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development.

Xiao ZD, Han L, Lee H, Zhuang L, Zhang Y, Baddour J, Nagrath D, Wood CG, Gu J, Wu X, Liang H, Gan B.

Nat Commun. 2017 Oct 4;8(1):783. doi: 10.1038/s41467-017-00902-z.

31.

Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma.

Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X.

Carcinogenesis. 2017 Oct 26;38(11):1129-1135. doi: 10.1093/carcin/bgx083.

32.

Editorial Comment.

Karam JA, Wood CG.

J Urol. 2018 Jan;199(1):52. doi: 10.1016/j.juro.2017.04.125. Epub 2017 Sep 22. No abstract available.

PMID:
28945990
33.

Local Tumor Bed Recurrence Following Partial Nephrectomy in Patients with Small Renal Masses.

Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, Matin SF, Wood CG, Karam JA.

J Urol. 2018 Feb;199(2):393-400. doi: 10.1016/j.juro.2017.09.072. Epub 2017 Sep 20.

PMID:
28941919
34.

Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.

Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, Briganti A, Montorsi F, Xylinas E, Shariat SF; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Cancer Group and the Upper Tract Urothelial Carcinoma Collaboration group.

BJU Int. 2018 Feb;121(2):252-259. doi: 10.1111/bju.14020. Epub 2017 Oct 12.

35.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

36.

Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.

Metcalfe M, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF.

J Endourol. 2017 Sep;31(9):946-953. doi: 10.1089/end.2016.0871. Epub 2017 Jul 21.

37.

Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.

Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG.

J Urol. 2018 Jan;199(1):53-59. doi: 10.1016/j.juro.2017.07.042. Epub 2017 Jul 18.

38.

Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy.

Rieken M, Shariat SF, Karam JA, Foerster B, Khani F, Gust K, Abufaraj M, Wood CG, Weizer AZ, Raman JD, Guo CC, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Bachmann A, De Marzo AM, Robinson BD, Margulis V.

J Urol. 2017 Dec;198(6):1269-1277. doi: 10.1016/j.juro.2017.06.096. Epub 2017 Jul 12.

PMID:
28709887
39.

The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma.

Chéry L, Borregales LD, Fellman B, Urbauer DL, Garg N, Parker N, Katz MHG, Wood CG, Karam JA.

Urology. 2017 Oct;108:114-121. doi: 10.1016/j.urology.2017.05.056. Epub 2017 Jul 10.

40.

Renal Medullary Carcinoma: Establishing Standards in Practice.

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK.

J Oncol Pract. 2017 Jul;13(7):414-421. doi: 10.1200/JOP.2017.020909. Review.

41.

Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V.

J Urol. 2017 Dec;198(6):1253-1262. doi: 10.1016/j.juro.2017.06.086. Epub 2017 Jun 28.

PMID:
28668287
42.

Potential Susceptibility Loci Identified for Renal Cell Carcinoma by Targeting Obesity-Related Genes.

Shu X, Purdue MP, Ye Y, Tu H, Wood CG, Tannir NM, Wang Z, Albanes D, Gapstur SM, Stevens VL, Rothman N, Chanock SJ, Wu X.

Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1436-1442. doi: 10.1158/1055-9965.EPI-17-0141. Epub 2017 Jun 16.

43.

Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.

Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Zhang S, Matin S, Karam JA, Wood CG, Wu X.

Cancer. 2017 Sep 15;123(18):3617-3627. doi: 10.1002/cncr.30707. Epub 2017 May 23.

44.

Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.

Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM.

J Urol. 2017 Sep;198(3):530-537. doi: 10.1016/j.juro.2017.04.067. Epub 2017 Apr 11.

45.

Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus.

Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, Lorentz CA, Bloom E, Bauman TM, Wood CG, Blute ML Jr.

J Urol. 2017 Oct;198(4):810-816. doi: 10.1016/j.juro.2017.04.066. Epub 2017 Apr 12.

46.

Testis-specific ATP synthase peripheral stalk subunits required for tissue-specific mitochondrial morphogenesis in Drosophila.

Sawyer EM, Brunner EC, Hwang Y, Ivey LE, Brown O, Bannon M, Akrobetu D, Sheaffer KE, Morgan O, Field CO, Suresh N, Gordon MG, Gunnell ET, Regruto LA, Wood CG, Fuller MT, Hales KG.

BMC Cell Biol. 2017 Mar 23;18(1):16. doi: 10.1186/s12860-017-0132-1.

47.

Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.

Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA.

J Urol. 2017 Aug;198(2):281-288. doi: 10.1016/j.juro.2017.03.011. Epub 2017 Mar 6.

PMID:
28268170
48.

Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma.

Leal I, Milbury K, Engebretson J, Matin S, Jonasch E, Tannir N, Wood CG, Cohen L.

Palliat Support Care. 2018 Apr;16(2):146-154. doi: 10.1017/S1478951517000074. Epub 2017 Mar 6.

49.

Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.

Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C.

Ann Surg. 2018 Jul;268(1):172-178. doi: 10.1097/SLA.0000000000002195.

PMID:
28257320
50.

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era.

Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E.

Clin Genitourin Cancer. 2017 Jun;15(3):363-370. doi: 10.1016/j.clgc.2017.01.010. Epub 2017 Jan 18.

PMID:
28216278

Supplemental Content

Support Center